VERAXA Biotech AG (NASDAQ: VRXA) announced a strategic collaboration with Ardigen S.A., an AI-driven bioinformatics company, to enhance the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will focus on creating AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
The integration of artificial intelligence into VERAXA's research and development strategy is expected to enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. VERAXA believes that this collaboration will strengthen the development of precision oncology therapies and improve long-term drug development success rates. According to the company, the partnership with Ardigen represents a significant step forward in leveraging computational approaches to address the complexities of cancer biology.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. Founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology, VERAXA aims to bring novel therapies to patients in need.
The BiTAC(R) platform is a registered trademark of VERAXA Biotech GmbH. For more details about this announcement, visit the full press release at https://ibn.fm/GLFg2. Additionally, the latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
This collaboration underscores the growing trend of incorporating AI into biopharmaceutical research to accelerate drug discovery and improve therapeutic outcomes. By combining VERAXA's expertise in antibody-based therapeutics with Ardigen's AI capabilities, the partnership has the potential to unlock new possibilities in cancer treatment, particularly in identifying more effective and safer drug candidates. The focus on dual-target combinations could lead to therapies that are more precise and less toxic, addressing a key challenge in oncology.
